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Abstract: The major feature of COPD is a progressive airflow limitation caused by chronic 
airway inflammation and consequent airway remodeling. Modified arginase and nitric oxide 
synthase (NOS) pathways are presumed to contribute to the inflammation and fibrosis. 
Asymmetric dimethylarginine (ADMA) may shunt L-arginine from the NOS pathway to the 
arginase one by uncoupling and competitive inhibition of NOS and by enhancing arginase 
activity. To attest the interplay of these pathways, the relationship between ADMA and airflow 
limitation, described by airway resistance (R
aw
), was investigated in a cohort of COPD patients. 
Every COPD patient willing to give consent to participate (n=74) was included. Case history, 
laboratory parameters, serum arginine and ADMA, pulmonary function (whole-body plethys-
mography), and disease-specific quality of life (St George’s Respiratory Questionnaire) were 
determined. Multiple linear regression was used to identify independent determinants of R
aw
. 
The final multiple model was stratified based on symptom control. The log R
aw
 showed significant 
positive correlation with log ADMA in the whole sample (Pearson’s correlation coefficient: 0.25, 
P=0.03). This association remained significant after adjusting for confounders in the whole data 
set (β: 0.42; confidence interval [CI]: 0.06, 0.77; P=0.022) and in the worse-controlled stratum 
(β: 0.84; CI: 0.25, 1.43; P=0.007). Percent predicted value of forced expiratory flow between 
25% and 75% of forced vital capacity showed that significant negative, elevated C-reactive 
protein exhibited significant positive relationship with R
aw
 in the final model. Positive correlation 
of R
aw
 with ADMA in COPD patients showing evidence of a systemic low-grade inflammation 
implies that ADMA contributes to the progression of COPD, probably by shunting L-arginine 
from the NOS pathway to the arginase one.
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Introduction
COPD is projected to become the third most common cause of death and the seventh 
leading cause of disability-adjusted life years by 2030.1 Furthermore, COPD poses 
great direct economic burden, as 3.36% of total health care budget is estimated to 
be allocated for covering the direct costs of COPD management.2 Despite immense 
efforts, the complex pathological mechanisms underlying COPD are incompletely 
understood yet.
The key symptom of COPD is a persistent airflow limitation that progresses over 
time paralleled by prolonged and abortive inflammatory response in the airways given 
inhaled irritant particles (eg, smoke)3 and low-grade systemic inflammation.4 Chronic 
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inflammation causes oxidative stress and mostly irreversible 
structural changes manifested in emphysema and small air-
way fibrosis,5 both of which lead to persistent and progressive 
lower airway obstruction, the cause of airflow limitation 
(and consequent hypoxia).6 This altered tissue microenvi-
ronment enhances the metabolism of extracellular matrix 
components such as collagen. Given its high turnover, even 
small changes in collagen production may cause significant 
collagen accumulation.3
Modified arginase and nitric oxide synthase (NOS) 
pathways may contribute to the increased collagen formation 
and fibrosis in COPD (Figure 1). Expression of both arginase 
and inducible NOS (iNOS) was shown to be increased in 
COPD. Arginase inhibition was reported to prevent airway 
inflammation and remodeling in animal models of COPD.7 
Accordingly, arginase activity exhibited significant negative 
correlation with spirometry parameters descriptive of airway 
flow (pre- and post-bronchodilator forced expiratory volume 
in 1 s as a percent of predicted value [FEV
1
% pred]).8
Asymmetric dimethylarginine (ADMA), an end product 
of degradation of methylated nuclear proteins, has diverse 
effects influential of the arginase and NOS pathways. 
ADMA has been shown to shunt L-arginine away from the 
NOS pathway toward the arginase path. In addition, ADMA 
induces uncoupling of NOS. The uncoupled NOS transfers 
electrons to ferrous-dioxygen, which eventually results in 
the formation of reactive oxygen and nitrogen species.9,10 
Previously, increased production of these reactive agents in 
response to ADMA was demonstrated in airway epithelium.11 
ADMA, administered in vitro, was reported to increase 
oxidative stress and induce apoptosis.12 In addition, ADMA 
competitively inhibits NOS, thus limiting nitric oxide (NO) 
liberation. This latter effect is more pronounced for the 
constitutive isoforms, the endothelial and neuronal NOSs 
(eNOS and nNOS, respectively), than for iNOS, an effect 
reflected by a weak iNOS inhibition in cytokine-stimulated 
lung epithelial cells.13 Furthermore, ADMA was reported to 
enhance arginase activity and consequent collagen formation 
in lung fibroblasts. Moreover, ADMA infusion significantly 
increased airway resistance (R
aw
) and diminished dynamic 
compliance in response to methacholine in a murine model.14 
The reciprocal regulation of arginase and NOS12 is further 
augmented by the interplay of intermediary products of these 
pathways: spermine, a byproduct of the arginase path, inhibits 
NOS,8 and N-hydroxy-L-arginine, a metabolite in the NOS 
pathway, blunts the arginase enzyme (Figure 1).15
Starting from the above-mentioned complex interactions 
among pathways, we set out to investigate the relationship 
between ADMA and airflow limitation described by R
aw
 in 
a cohort of COPD patients.
Methods
study design and protocol
The present study was planned in line with the STROBE 
statement for cross-sectional studies16 and was approved 
by the Ethical Committee of the University of Debrecen 
Figure 1 The influence of ADMA on the NOS and arginase pathways in COPD.
Notes: green arrows denote activation and enhancement. red lines denote inhibition. Black arrows denote transformation or metabolic connection.
Abbreviations: aDMa, asymmetric dimethylarginine; nOs, nitric oxide synthase; l-arg, l-arginine; nOha, n-hydroxy-l-arginine; nO, nitric oxide; OnOO-, peroxynitrite 
anion; PrMT, protein methyltransferase; DDah, dimethylarginine dimethylaminohydrolase (or dimethylargininase); enOs, endothelial nOs; inOs, inducible nOs.
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(DEOEC RKEB/IKEB 3632-2012). Informed consent was 
obtained from each participant. The investigation conforms 
to the principles outlined in the Declaration of Helsinki.
The current study is based on an investigation of 
patients who attended the outpatient unit of the Depart-
ment of Pulmonology (University of Debrecen) between 
September 1, 2012 and October 15, 2013 for the manage-
ment of any of the following chronic inflammatory airway 
diseases: bronchial asthma (BA), COPD, asthma–COPD 
overlap syndrome (ACOS), and allergic rhinitis (AR). All 
patients who did not have any acute inflammatory disease 
over the preceding 1 month and either benign or malignant 
tumors in the history were invited to participate in the study. 
Overall, 319 patients were recruited (BA: n=167, COPD: 
n=74, ACOS: n=21, and AR: n=56).
For the present study, data of patients who were treated 
for COPD (n=74) were analyzed. At the time of recruit-
ment, patients were already diagnosed with COPD and 
were managed according to the relevant Hungarian practice 
guideline17 and the Global initiative for chronic Obstructive 
Lung Disease (GOLD).18 Airway limitation was defined 
using the lower limit of normal.19–21 Patients received therapy 
at the time of inclusion as clinically warranted. Whole-
body plethysmography was performed for every patient to 
determine lung function parameters including R
aw
, which was 
selected as the main outcome measure. R
aw
 is reflective of 
alterations in alveolar pressure over changes in flow and is 
highly dependent on state of airways, and thus, it is an optimal 
parameter for the quantification of airflow limitation.22 
Demographic, anthropometric, anamnestic, laboratory, 
and quality-of-life data were also acquired. Cumulative 
measure of smoking exposure was described by pack-years 
(accounted for both past and current smoking exposure). To 
assess disease-specific quality of life, the official Hungarian 
version of St George’s Respiratory Questionnaire (SGRQ)23 
was used with the permission of the proprietor (Paul Jones, 
University of London, London, UK).
Pulmonary function testing
Whole-body plethysmography was performed according 
to the American Thoracic Society/European Respiratory 
Society criteria24,25 with Piston whole-body plethysmograph 
(PDT-111/p; Piston Medical, Budapest, Hungary) equipped 
with automatic body temperature- and pressure-saturated 
correction for cabin temperature, humidity, and pressure 
and with full automatic calibration and leakage test. Patients 
were directed to take their usual medication on the morning 
of their examination, so plethysmography was performed 
while patients were receiving long-term therapy for COPD. 
The best of three technically sound maneuvers was selected 
for each participant. Regarding resistance curves, at least 
two separate and technically appropriate measurements were 
performed (each measurement consisted of recordings of at 
least five resistance loops), and results were accepted only if 
these were the same for both measurements. Lung function 
data and, if algorithms of the manufacturer were available, 
percent predicted of normal reference values were obtained: 
R
aw
, airway conductance (G
aw
 = 1/R
aw
), FEV
1
% pred, forced 
vital capacity as a percent of predicted value (FVC% pred), 
ratio of FEV
1
 to FVC (FEV
1
/FVC = FEV
1
% = Tiffeneau 
index), forced expiratory flow between 25% and 75% of FVC 
as a percent of predicted value (FEF
25–75%
% pred), residual 
volume as a percent of predicted value (RV% pred), total 
lung capacity as a percent of predicted value (TLC% pred), 
ratio of RV to TLC as a percent of predicted value (RV/
TLC% pred), ratio of inspiratory capacity to TLC (IC/TLC), 
inspiratory vital capacity as a percent of predicted value 
(IVC% pred), ratio of FEV
1
 to IVC as a percent of predicted 
value (FEV
1
/IVC% pred), thoracic gas volume as a percent 
of predicted value (TGV% pred), peak expiratory flow as a 
percent of predicted value (PEF% pred), maximal expira-
tory flow at 50% of FVC as a percent of predicted value 
(MEF
50%
% pred). Parameters showing Gaussian distribution 
were used in their raw forms, whereas those not normally 
distributed were appropriately transformed to obtain normal 
distribution.
Blood samples
After an overnight fast, blood samples were drawn on the 
morning of the examination. Routine laboratory investigations 
were done according to the standard clinical practice of the 
Department of Laboratory Medicine (University of Debrecen). 
Serum or plasma samples were used for determining mea-
sures descriptive of carbohydrate homeostasis (glucose, 
insulin, hemoglobin A1c [HgA1c]), lipid homeostasis (total 
cholesterol, triglyceride, low-density lipoprotein [LDL]-
cholesterol, high-density lipoprotein [HDL]-cholesterol, 
lipoprotein(a), apolipoprotein A1 [ApoA1], apolipo-
protein B [ApoB]), metabolism of L-arginine (folic acid, 
vitamin B12, urea), kidney function (glomerular filtration 
rate, urea, creatinine), liver function (glutamate–oxaloacetate 
transaminase, glutamate–pyruvate transaminase, gamma-
glutamyltransferase), status of skeletal muscles (creatine 
kinase [CK], lactate dehydrogenase), and systemic inflam-
mation (C-reactive protein [CRP], procalcitonin, fibrinogen). 
In addition to the use of serum CRP concentration, patients 
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were dichotomized as having high vs normal CRP level with 
the cutoff being 4.6 mg/L and 5.2 mg/L for female and male 
patients, respectively (these are the reference values used 
in routine clinical practice by the Department of Labora-
tory Medicine, University of Debrecen). Serum samples 
used to determine L-arginine, ADMA, and symmetric 
dimethylarginine (SDMA) were frozen within 60 min and 
stored at -80°C until further analysis.
Determination of aDMa and other 
arginine derivatives
Arginine and its derivatives were measured as previously.26,27 
Briefly, 250 μL of serum was mixed with the internal stan-
dard (50 μL of 1,000 μmol/L L-homoarginine hydrochloride 
from Sigma-Aldrich Co., St Louis, MO, USA) and borate 
buffer (700 μL, pH 9.0). This mixture was passed through 
solid-phase extraction cartridges (OASIS MCX 3cc) apply-
ing a 12-column manifold (J.T. Baker, Phillipsburg, NJ, 
USA). After successive washing with borate buffer (pH 9.0), 
deionized water, and methanol (Scharlau, Sentmenat, 
Spain), the sample (containing the arginine derivatives) 
was eluted with 1 mL of ammonia–water–methanol solution 
(10/40/50, v/v/v) (Reanal, Budapest, Hungary). The solvent 
was evaporated in vacuum under nitrogen atmosphere to 
dryness at 60°C, and then the residue was dissolved in 
200 μL of deionized water. This solution was used for 
derivatization.
For derivatization, the sample (200 μL) was mixed with 
63 μL of ortho-phthaldialdehyde/3-mercaptopropionic 
acid fluorescent reagent solution, incubated at 22°C for 
10 min, and then kept at 5°C until the measurements. 
Chromatographic system of a Waters 2695 Separations 
Module equipped with thermostable autosampler (5°C) 
and column module (35°C), a Waters 2745 Fluores-
cence Detector (Waters, Milford, MA, USA), and a C-18 
(4.6×150 mm, 3.5 μm) column were used for analysis. A 
sample (10 μL) was injected into the chromatographic 
system. Gradient elution at 1 mL/min flow rate was applied 
using mobile phase A (20 mmol/L of (NH
4
)
2
CO
3
 in water, 
pH adjusted to 7.5±0.05 with formic acid) and mobile phase 
B (acetonitrile). The gradient condition was as follows: 
0–13 min: 91% A and 9% B; 13–15 min: linear change to 
70% A and 30% B holding this setting for additional 5 min; 
and 20–20.1 min: linear change to 91% A and 9% B holding 
this for 35 min.
Analytes were detected at λ
ex
=337 nm, while λ
em
=520 nm 
was used for arginine and homoarginine and λ
em
=454 nm for 
ADMA and SDMA.
st george’s respiratory Questionnaire
The official Hungarian version of SGRQ, validated for a 
1-month recall period reflective of the patients’ recollection 
of their symptoms, was used according to the SGRQ manual 
supplied by the proprietor.28 SGRQ quantifies health impair-
ment with three component scores and one total score. The 
Symptoms score describes the effect, frequency, and severity 
of respiratory symptoms based on the patients’ perception 
of their recent respiratory problems; Activity score quanti-
fies the impairment in the daily physical activity; Impacts 
score includes a wide array of disturbances related to the 
psychosocial function; and the Total score sums up the 
significance of the disease on overall health status. All scores 
are expressed as a percentage, with 100% representing the 
worst and 0% indicating the best subjective health status. 
Differences in scores were considered clinically meaningful 
if they exceeded 4% points.29 The questionnaire was self-
administered under supervision. Data entry was performed 
by two independent raters who diligently followed the data 
entry guidelines. Interrater variability assessed by Spearman’s 
correlation was 0.99 (P,0.001), 0.988 (P,0.001), 0.999 
(P,0.001), and 0.999 (P,0.001) for the Symptoms, Activity, 
Impacts, and Total scores, respectively. The mean of scores 
provided by the two raters was used for statistical analysis.
To assess the extent of symptom control, data were 
dichotomized with respect to the Symptoms score compo-
nent. Patients with a Symptoms score ,32.66% were put in 
the better-controlled group, while patients with a Symptoms 
score $32.66% formed the worse-controlled group (32.66% 
was the median Symptoms score of the whole cohort). 
This dichotomization was used for stratification of the final 
multiple regression model.
statistical analysis
Normality of continuous variables was checked by the 
Shapiro–Wilk test. In case of Gaussian distribution, Student’s 
t-test was used for the comparison of two data sets; if not, 
Mann–Whitney U test was carried out. Frequencies were 
compared using Pearson’s χ2 test.
Demographic, anthropometric, anamnestic, laboratory, 
and SGRQ data were divided into two groups with lower 
and higher R
aw
 (using the median value of R
aw
 as a cutoff 
level) for comparison. Thus, patients with R
aw
,0.27 kPa⋅s/L 
formed the lower R
aw
 group (n=34), while the higher R
aw
 
group (n=40) contained patients with R
aw
$0.27 kPa⋅s/L. 
In addition, demographic, anthropometric, pulmonary 
function, and SGRQ data were compared in terms of symptom 
control achieved in our cohort (herein n=73; SGRQ data were 
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missing for one patient). Dichotomy of patients based on the 
median of Symptoms scores as a cutoff level provided a better-
controlled (,32.66) group (n=37) and a worse-controlled 
($32.66) one (n=36) (loss of one patient in this approach 
was due to the lack of the SGRQ result for this patient).
The relationship between R
aw
 and serum ADMA level 
was investigated with Pearson’s correlation as well as 
with simple and multiple linear regression. To ensure nor-
mal distribution of variables for these analyses, CK, total 
cholesterol, LDL-cholesterol, HDL-cholesterol, ApoA1, 
ApoB, insulin, HgA1c, folate, thyroid-stimulating hormone 
(sensitive), ADMA, homeostatic model assessment index, 
R
aw
, FEF
25–75%
, RV, and RV% pred were log-transformed, 
and reciprocal of square of glucose concentration was 
computed.
To identify determinants of R
aw
 as well as ADMA, 
simple linear regression was carried out including traditional 
confounding factors (age, gender, height, disease duration 
in years), lung function parameters, laboratory parameters 
characteristic of carbohydrate, lipid, and arginine homeo-
stasis, hepatic, kidney, and skeletal muscle function, and 
furthermore, systemic markers of inflammation. Missing 
data were omitted. Then, in order to eliminate effects of 
potential confounders, multiple linear regression modeling 
was performed including all significant regressors determined 
with the simple linear regression as well as age and gender 
(as a priori variables). Inclusion of the defined daily dose of 
steroids into the initial model should be noted. Variables were 
introduced into the initial multiple model simultaneously, and 
then factors not contributing significantly to the model were 
deleted. In addition, the final model was stratified with respect 
to the better or worse symptom control dichotomized by the 
median of Symptoms scores of SGRQ. Heteroskedasticity 
and goodness of fit for the model were assessed by Cook–
Weisberg and Ramsey test.
Statistical analysis was performed with Stata 13.0 
software (Stata Corporation). Values are given as mean ± 
standard deviation (SD) or median (with the interquartile 
range [IQR]), and regression coefficients are presented with 
their 95% confidence interval (CI).
Results
Patients
Of the 74 COPD patients involved in the present study, 
two were treatment-naïve at the time of inclusion. Overall, 
64 patients received inhaled anticholinergics either alone 
(n=63) or in fixed combination with a beta adrenoceptor agonist 
(ipratropium with fenoterol) (n=6). Furthermore, 60 patients 
received inhaled corticosteroids in fixed combination 
with long-acting beta agonists. Overall, 24 patients received 
inhaled short-acting beta agonists, and three patients received 
inhaled long-acting beta agonists as a monotherapy. Other 
medications included oral use of methylxanthines (n=30) 
and montelukast (n=3).
Comparison of patients with lower and 
higher airflow resistance
The two groups, dichotomized with respect to the median 
of R
aw
 values, were proved to be homogenous regarding 
most of the parameters investigated. However, the average 
of patient’s age was moderately higher, while the average 
of years of smoking, pack-years, and all SGRQ scores was 
substantially higher in the patient group with higher R
aw
. 
Nevertheless, there was no significant difference in the 
prevalence of smoking at the time of the investigation. The 
height of patients was slightly but statistically significantly 
smaller in the higher R
aw
 group. Although the median of CRP 
level among patients with higher R
aw
 was only on the verge 
of statistical significance (P=0.052), frequency of elevated 
CRP was significantly greater in the higher R
aw
 group than 
in the lower R
aw
 group (Table 1).
Comparison of the better-controlled and 
worse-controlled patients
Demographic and anthropometric parameters did not differ 
significantly when the patient cohort was compared across 
level of disease control (better-controlled vs worse-controlled) 
(Table 2). Lung function parameters describing the flow in 
the airways and G
aw
 were significantly lower in the worse-
controlled group. Consistent with this, TGV% pred, RV% 
pred, RV/TLC% pred, and R
aw
 were significantly higher 
among patients in the worse-controlled group. All SGRQ 
scores were substantially higher in the worse-controlled 
group (showing greater health impairment and poorer quality 
of life) (Table 2).
Significant predictors of Raw and serum 
aDMa concentration
The median serum ADMA levels were practically the same in 
all patient groups, that is, 0.58 (IQR: 0.44–0.67) μmol/L, 0.58 
(IQR: 0.43–0.64) μmol/L, and 0.58 (IQR: 0.46–0.7) μmol/L 
in the whole data set and in strata of patients with lower and 
higher R
aw
, respectively. Upon assessing the linear relation-
ship between log R
aw
 and log ADMA, we found significant 
positive correlation in the whole data set (Figure 2) and 
in the worse-controlled stratum (Pearson’s correlation 
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Table 1 Characteristics of the whole population of COPD patients (n=74) and of its two groups containing patients with lower (n=34) 
and higher (n=40) raw values
Parameters Whole population Lower Raw Higher Raw P-value
age (years) 62.15±9.70 59.53±7.92 64.38±10.58 0.031
gender (female/male) 27/47 12/22 15/25 0.844
smoker (no/yes) 49/25 23/11 26/14 0.810
smoking (pack-years) 20.00 (5.25–33.75) 17.50 (2.25–25.00) 26.68 (8.38–39.40) 0.035
smoking (years) 10.00 (0.00–33.00) 0.50 (0.00–20.00) 20.00 (0.00–40.00) 0.031
Diabetes (no/yes) 61/13 29/5 32/8 0.551
Dyslipidemia (no/yes) 48/26 23/11 25/15 0.644
rr systolic (mmhg) 136.49±15.85 134.18±14.65 138.45±16.74 0.251
rr diastolic (mmhg) 82.38±14.06 80.85±15.24 83.68±13.04 0.393
hypertension (no/yes) 31/43 18/16 13/27 0.076
aMI (no/yes) 65/9 29/5 36/4 0.537
stroke (no/yes) 73/1 33/1 40/0 0.275
Disease duration (years) 5.00 (3.00–10.00) 5.50 (3.00–10.00) 5.00 (3.00–9.00) 0.798
Waist (cm) 101.99±14.31 102.25±14.01 101.78±14.74 0.888
Weight (kg) 79.71±17.12 81.55±17.44 78.15±16.92 0.406
height (m) 1.68±0.094 1.71±0.086 1.65±0.091 0.003
BMI (kg/m2) 28.19±5.09 27.61±4.94 28.68±5.23 0.380
aDMa (μmol/l) 0.58 (0.44–0.67) 0.58 (0.43–0.64) 0.58 (0.46–0.70) 0.354
sDMa (μmol/l) 0.48 (0.42–0.58) 0.49 (0.42–0.57) 0.48 (0.41–0.62) 0.425
l-arginine (μmol/l) 104.20±28.81 107.70±28.71 101.23±28.92 0.339
B12 (pmol/l) 302.40 (237.70–348.50) 308.00 (243.10–347.30) 288.75 (224.35–348.65) 0.498
Folate (nmol/l) 17.85 (13.74–23.47) 18.49 (14.91–23.86) 16.92 (12.71–22.84) 0.293
Urea (mmol/l) 5.31±1.37 5.37±1.35 5.26±1.40 0.731
Creatinine (μmol/l) 71.00 (61.00–81.00) 70.50 (58.00–90.00) 73.50 (61.00–79.00) 0.576
gFr (ml/min/1.73 m2) 91.00 (80.00–91.00) 88.50 (80.00–91.00) 91.00 (80.50–91.00) 0.677
gOT (U/l) 19.50 (15.00–23.00) 20.50 (16.00–23.00) 19.00 (14.00–23.00) 0.254
gPT (U/l) 18.00 (14.00–24.00) 20.00 (13.00–26.00) 18.00 (15.00–24.00) 0.490
γgT (U/l) 32.50 (20.00–49.00) 31.00 (20.00–49.00) 33.00 (19.50–47.00) 0.991
CK (U/l) 101.00 (74.00–139.00) 106.00 (74.00–165.00) 99.00 (76.00–135.50) 0.591
lDh (U/l) 208.62±34.98 204.15±36.82 212.43±33.32 0.314
glucose (mmol/l) 5.00 (4.20–5.80) 5.00 (4.00–5.60) 5.10 (4.60–6.25) 0.462
Insulin (mU/l) 8.95 (5.55–16.50) 10.15 (5.65–15.35) 7.80 (5.25–19.85) 0.892
hga1c (%) 5.70 (5.50–6.10) 5.60 (5.40–6.10) 5.80 (5.50–6.20) 0.295
hOMa 2.14 (1.14–4.67) 2.14 (1.23–3.64) 2.15 (1.05–5.21) 0.910
Cholesterol (mmol/l) 5.30 (4.00–6.30) 5.60 (5.00–6.30) 5.00 (4.00–6.15) 0.159
lDl-C (mmol/l) 3.10 (2.60–3.70) 3.20 (2.60–3.80) 2.85 (2.4–3.65) 0.116
hDl-C (mmol/l) 1.40 (1.20–1.80) 1.45 (1.20–1.80) 1.40 (1.10–1.80) 0.752
apoa1 (g/l) 1.55 (1.38–1.80) 1.61 (1.47–1.76) 1.52 (1.33–1.85) 0.365
apoB (g/l) 1.00 (0.85–1.28) 1.00 (0.91–1.28) 0.95 (0.83–1.19) 0.219
lp(a) (mg/l) 129.50 (58.00–455.00) 136.00 (38.00–568.00) 106.50 (59.50–363.50) 0.991
Tg (mmol/l) 1.35 (1.00–2.00) 1.70 (1.00–2.00) 1.20 (0.90–1.85) 0.256
CrP (mg/l) 2.00 (1.210–4.00) 1.85 (1.210–3.10) 2.80 (1.25–6.65) 0.052
CrP (normal/high) 58/16 31/3 27/13 0.014
Fibrinogen (g/l) 3.67 (3.25–4.00) 3.56 (3.12–4.03) 3.77 (3.35–4.00) 0.282
Procalcitonin (μg/l) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.278
sTsh (mU/l) 1.26 (0.84–1.93) 1.30 (0.76–2.16) 1.21 (0.84–1.67) 0.558
sgrQ symptoms score 32.66 (13.64–58.28) 25.55 (8.28–36.98) 40.46 (21.54–68.19) 0.004
sgrQ Impacts score 29.64 (15.44–49.79) 20.85 (11.00–38.70) 36.58 (22.20–52.67) 0.011
sgrQ activity score 57.32 (47.24–72.08) 53.25 (23.41–66.09) 65.39 (53.57–72.91) 0.008
sgrQ Total score 41.08±20.99 33.82±21.46 47.07±18.81 0.006
Notes: Patients with raw,0.27 kPa⋅s/l formed the lower raw group, while patients with raw$0.27 kPa⋅s/l were put in the higher raw group (0.27 kPa⋅s/l was the median 
raw of the whole cohort). Data are presented as mean ± sD or median (interquartile range) unless otherwise stated. Differences between the two groups were considered 
significant at P,0.05 (indicated in bold). Clinically meaningful differences of sgrQ results are underlined.
Abbreviations: raw, airway resistance; rr, blood pressure (measured according to riva-rocci); aMI, acute myocardial infarction; BMI, body mass index; aDMa, asymmetric 
dimethylarginine; SDMA, symmetric dimethylarginine; GFR, glomerular filtration rate; GOT, glutamate–oxaloacetate transaminase; GPT, glutamate–pyruvate transaminase; 
γgT, gamma-glutamyltransferase; CK, creatinine kinase; lDh, lactate dehydrogenase; hga1c, hemoglobin a1c; hOMa, homeostatic model assessment; lDl-C, low-density 
lipoprotein-cholesterol; hDl-C, high-density lipoprotein-cholesterol; apoa1, apolipoprotein a1; apoB, apolipoprotein B; lp(a), lipoprotein(a); Tg, triglyceride; CrP, 
C-reactive protein; sTsh, thyroid-stimulating hormone-sensitive; sgrQ, st george’s respiratory Questionnaire; sD, standard deviation.
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coefficient: 0.25 and 0.35; P=0.03 and P=0.04, respectively). 
However, there was a considerably weaker and statistically 
nonsignificant correlation in the better-controlled stratum 
(Pearson’s correlation coefficient: 0.08, P=0.61).
In accordance with results of the correlation analysis, 
simple linear regression (used to identify factors significantly 
determining R
aw
 as well as ADMA) revealed that log R
aw
 and 
log ADMA are mutually significant predictors of each other 
(Table 3). After adjusting for all significant predictors and a 
priori determinants by means of multiple linear regression, the 
positive association between log R
aw
 and log ADMA remained 
significant (β: 0.42; CI: 0.06, 0.77; P=0.022) (Table 3). This 
positive association of log R
aw
 with log ADMA became even 
more pronounced in the worse-controlled stratum of COPD 
patients (β: 0.84; CI: 0.25, 1.43; P=0.007), while only a 
weak and statistically nonsignificant association was present 
in the better-controlled stratum (β: -0.17; CI: -0.61, 0.27; 
P=0.45). The Cook–Weisberg test showed no heteroske-
dasticity for the full model, the worse-controlled stratum, 
and the better-controlled stratum (P=0.18, P=0.74, and P=0.39, 
respectively). Furthermore, all three models showed good 
fit reflected by the locally weighted scatterplot smoothing 
(Figure 3) as well as by the Ramsey test (P=0.75, P=0.67, and 
P=0.15 for the whole data set, the worse-controlled stratum, 
and the better-controlled stratum, respectively).
In addition, the final multiple linear regression model 
(built for R
aw
) indicated that presence of elevated CRP 
confers significant impact on COPD (ie, elevated CRP is 
associated with higher R
aw
). We also found that log FEF
25–75%
 
% pred, the lung function parameter descriptive of small 
airway dysfunction, showed negative association with 
log R
aw
 (β: -0.33; CI: -0.51, -0.15; P,0.001) (Table 3). 
Consistent with this latter finding, there was a strong 
significant positive correlation between log G
aw
 and log 
FEF
25–75%
 % pred in the whole sample, in the worse-controlled 
stratum and in the better-controlled stratum too (Pearson’s 
correlation coefficient: 0.53, 0.40, and 0.57; P,0.001, 
P=0.017, and P,0.001, respectively).
Table 2 Main characteristics of the whole population of COPD patients (having complete sgrQ data; n=73) and of its better-
controlled (n=37) and worse-controlled (n=36) groups
Parameters Whole population Better-controlled Worse-controlled P-value
Demographic and anthropometric parameters
age (years) 62.01±9.70 61.32±8.35 62.72±10.99 0.542
gender (female/male) 27/46 13/24 14/22 0.740
height (m) 1.68±0.09 1.70±0.10 1.66±0.08 0.083
Weight (kg) 79.61±17.22 82.36±18.65 76.77±15.37 0.173
lung function test parameters
FVC% pred 82.30±17.44 87.46±16.58 77.00±16.90 0.009
IVC% pred 87.00 (74.00–100.00) 89.00 (78.00–100.00) 85.00 (70.00–99.50) 0.166
TlC% pred 113.00 (103.00–127.00) 108.00 (101.00–120.00) 121.50 (106.50–130.00) 0.086
TgV% pred 140.00 (123.00–167.00) 135.00 (116.00–155.00) 157.00 (126.50–178.50) 0.025
rV% pred 172.03±47.23 157.14±35.80 187.33±52.87 0.006
rV/TlC% pred 140.47±20.99 132.00±16.71 149.17±21.57 ,0.001
FeV1% pred 66.08±20.04 74.19±16.98 57.75±19.71 ,0.001
PeF% pred 52.00 (39.00–73.00) 58.00 (50.00–77.00) 41.50 (29.50–59.50) ,0.001
FeF25–75% % pred 35.00 (24.00–53.00) 42.00 (29.00–60.00) 28.50 (18.50–46.50) 0.006
MeF50% % pred 37.00 (20.00–58.00) 43.00 (32.00–63.00) 24.50 (16.00–49.00) ,0.001
FeV1/IVC% pred 76.11±16.36 82.19±13.36 69.86±16.96 ,0.001
FeV1/FVC 0.65 (0.54–0.74) 0.68 (0.64–0.76) 0.59 (0.48–0.71) 0.007
raw (kPa⋅s/l) 0.27 (0.22–0.42) 0.25 (0.20–0.31) 0.33 (0.26–0.53) 0.008
gaw (l/kPa⋅s) 3.67 (2.36–4.64) 3.96 (3.27–4.96) 3.07 (1.90–3.86) 0.007
sgrQ
symptoms score 32.66 (13.64–58.28) 13.64 (5.20–25.55) 60.02 (43.24–76.70) ,0.001
Impacts score 29.66 (17.09–49.79) 18.51 (10.10–29.66) 47.01 (31.34–54.40) ,0.001
activity score 59.45 (47.63–72.08) 52.14 (24.62–59.45) 66.41 (57.32–82.57) ,0.001
Total score 41.08±20.99 27.61±15.94 54.93±15.98 ,0.001
Notes: Patients in the better-controlled group had a symptoms score smaller than the median symptoms score (for the whole cohort), while symptoms score of patients in 
the worse-controlled group reached or exceeded this median value (32.66 was the median sgrQ symptoms score of the whole cohort). Data are presented as mean ± sD 
or median (interquartile range) unless otherwise stated. Differences between the two groups were considered significant at P,0.05 (indicated in bold). Clinically meaningful 
differences of sgrQ results are underlined. It should be noted that only 73 patients had complete sgrQ results.
Abbreviations: sgrQ, st george’s respiratory Questionnaire; FVC, forced vital capacity; IVC, inspiratory vital capacity; TlC, total lung capacity; TgV, thoracic gas 
volume; rV, residual volume; FeV1, forced expiratory volume in 1 s; PEF, peak expiratory flow; FEF25–75%, forced expiratory flow between 25% and 75% of FVC; MEF, maximal 
expiratory flow; Raw, airway resistance; gaw, airway conductance; sD, standard deviation.
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Furthermore, all SGRQ scores (including the Total score) 
showed clinically meaningful differences with respect to the 
extent of airflow limitation (lower R
aw
 group vs higher R
aw
 
group) as well as symptom control (worse-controlled stratum 
vs better-controlled stratum). Moreover, the Total score 
showed significant negative correlation with FEV
1
% pred 
(Pearson’s correlation coefficient: -0.43, P,0.001).
Discussion
The major finding of our study is that serum ADMA level of 
COPD patients shows significant positive correlation with 
airflow limitation indicated by R
aw
. Due to the numerous 
confounders, inherent of a clinically diverse population, mul-
tiple linear regression modeling was implemented. We found 
that the said strong positive correlation remained significant 
after the elimination of confounders. We identified two other 
influential parameters concerning airflow limitation: CRP, 
a serum marker of systemic inflammation, and FEF25–75% 
% pred, a dynamic pulmonary function parameter describing 
the function of small airways.30
CRP is an acute-phase reactant that is known as a stable 
biomarker for systemic inflammation.31 Analysis of the 
Lung Health Study with 4803 participants suffering from 
mild-to-moderate COPD concluded that serum CRP level is 
a significant predictor of future risk of death and cardiovas-
cular events in COPD, and it affords additional information 
beyond knowledge provided by traditional measures such 
as FEV
1
 and smoking habits.32 The clinical relevance of 
elevated CRP is undisputed, with serum levels above 1 mg/L 
being indicative of increased cardiovascular risk in healthy 
individuals.31 In our patient cohort, the serum CRP level was 
an independent predictor of R
aw
, and it remained significant 
even after the multiple linear regression (Table 3). More-
over, CRP proved to be significant in both strata of multiple 
linear regression (ie, worse-controlled and better-controlled 
groups). These results underline the fundamental role of 
inflammation in the evolution of COPD. It is worthy to note 
that the effect of elevated CRP was not influenced by the use 
Figure 2 Correlation of (log transformed values of) raw and serum concentration of 
aDMa in the whole data set (n=74).
Notes: The x-axis shows the common logarithm of serum aDMa concentration (in 
μmol/l), while the y-axis denotes the common logarithm of raw (in kPa⋅s/l). The blue 
line shows the fitted values of log ADMA and log Raw data pairs (represented by the 
green dots), while the gray zone indicates the 95% CI.
Abbreviations: raw, airway resistance; aDMa, asymmetric dimethylarginine; 
CI, confidence interval.
?
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Table 3 Significant predictors of ADMA serum level and 
raw determined with simple and multiple (for raw only) linear 
regression for the whole population of COPD patients (n=74)
Parameters Coefficient (95% CI) P-value
simple linear regression of aDMa (log transformed)
smoker 0.13 (0.006, 0.26) 0.039
log sDMa 1.28 (0.93, 1.63) ,0.001
Fibrinogen 0.11 (0.034, 0.19) 0.006
log raw 0.13 (0.012, 0.24) 0.030
simple linear regression of raw (log transformed)
age 0.019 (0.0076, 0.031) 0.002
height -1.72 (-2.97, -0.47) 0.008
Uric acid 0.0017 (0.00050, 0.0029) 0.006
Fibrinogen 0.18 (0.014, 0.34) 0.034
CrP (normal/high) 0.61 (0.35, 0.87) ,0.001
log aDMa 0.51 (0.049, 0.96) 0.030
sDMa 0.94 (0.032, 1.85) 0.043
FVC -0.32 (-0.44, -0.19) ,0.001
FVC% pred -0.0087 (-0.015, -0.0020) 0.012
FeV1 -0.42 (-0.56, -0.28) ,0.001
FeV1% pred -0.011 (-0.016, -0.0051) ,0.001
FeV1/FVC -0.015 (-0.024, -0.0059) 0.002
FeF25–75% -0.38 (-0.50, -0.25) ,0.001
log FeF25–75% % pred -0.49 (-0.68, -0.31) ,0.001
rV/TlC% 0.024 (0.013, 0.035) ,0.001
rV/TlC% pred 0.0080 (0.0025, 0.013) 0.005
IC/TlC -2.22 (-3.45, -0.98) 0.001
Corticosteroid use 0.31 (0.023, 0.60) 0.035
sgrQ symptoms score 0.0042 (-0.000083, 0.0086) 0.054
sgrQ activity score 0.0063 (0.0014, 0.011) 0.012
sgrQ Impacts score 0.0055 (-0.00023, 0.011) 0.060
sgrQ Total score 0.0060 (0.00033, 0.012) 0.038
Multiple linear regression of raw (log transformed)
log aDMa 0.42 (0.062–0.771) 0.022
log FeF25–75% % pred -0.336 (-0.517, -0.154) ,0.001
CrP (normal/high) 0.489 (0.266, 0.713) ,0.001
Notes: The symptoms and Impacts scores are also included, although these are 
on the verge of significance. Regression coefficient values are presented with their 
95% CIs. The initial model for the multiple regression analysis consisted of the 
significant parameters provided by the simple regression and the relevant a priori 
identified parameters (the latter ones were omitted from the present table as they 
did not contribute significantly to the final model). Bold represents statistically 
significant values.
Abbreviations: aDMa, asymmetric dimethylarginine; raw, airway resistance; 
CI, confidence interval; SDMA, symmetric dimethylarginine; CRP, C-reactive protein; 
FVC, forced vital capacity; FeV1, forced expiratory volume in 1 s; FeF25–75%, forced 
expiratory flow between 25% and 75% of FVC; RV, residual volume; TLC, total lung 
capacity; IC, inspiratory capacity; sgrQ, st george’s respiratory Questionnaire.
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of corticosteroids which is reflected by the lack of contribu-
tion to the model, leading to the omission of corticosteroid 
use from the final multiple regression model (Table 3).
Involvement of small airways in COPD is a central 
phenomenon that is critical regarding the progression of 
this disease. Infiltration of the wall of small airways with 
immune cells produces inflammatory exudate and airway 
wall thickening called remodeling.33 Accordingly, our result 
that FEF25–75% % pred was a significant independent 
predictor of R
aw
 (provided by both the simple and multiple 
linear regression; Table 3) reflects the strong involvement 
of the small airways in the evolution of airflow limitation 
in our COPD patient cohort. This finding corroborates the 
findings of others reporting that increase in resistance of 
small airways plays a significant role in airflow limitation 
developed in obstructive airway diseases.34
The major finding of the present study is that, in our 
cohort of COPD patients, there is a pronounced positive 
association between R
aw
 and serum ADMA level (Table 3), 
the extent of which exhibits an inverse relationship with 
the level of symptom control (ie, a stronger positive rela-
tionship between R
aw
 and ADMA accompanies with more 
severe symptoms according to the patient’s self-report). 
This result was presented by the final model of multiple 
regression, where data were stratified using the median of 
SGRQ Symptoms scores (containing information about 
the perception of symptoms over the preceding 4 weeks by 
quantifying responses with regard to wheezing, shortness of 
breath, sputum production, and exacerbations). During the 
analysis, the significant relationship between log R
aw
 and 
log ADMA seen in the whole patient cohort became even 
stronger in the worse-controlled group of patients, while it 
became weaker and statistically nonsignificant in the better-
controlled group. It may also be noted that, in agreement with 
prior reports,35,36 the Total score of SGRQ showed a strong 
negative relationship with FEV
1
%.
Based on the significant positive association between R
aw
 
and ADMA, as well as on the interaction between ADMA’s 
influence on R
aw
 and disease severity, we propose that 
ADMA contributes to the progression of COPD by shunt-
ing L-arginine toward the arginase pathway, by inducing 
uncoupling and competitive inhibition of iNOS (activated by 
the inflammation) as well as eNOS and nNOS (being active 
constitutively). As a result, increased polyamine formation 
producing cellular proliferation and fibrosis ensues paral-
lel to spermine’s inhibitory action of the constitutive NOS 
isoforms. The activity of uncoupled iNOS yields reactive 
agent formation that, in turn, has the propensity to induce 
expression of protein arginine methyltransferases (enzymes 
responsible for demethylation of L-arginine side chains in 
proteins) and to decrease the expression of dimethylarginine 
dimethylaminohydrolase (an enzyme responsible for ADMA 
degradation). These processes lead to a further increase of 
ADMA levels. Moreover, decrease of NO synthesis will 
lead to NO deficiency contributing to decreased mucociliary 
clearance and bactericidal activity, increased smooth muscle 
cell proliferation, and resultant increase of bronchial tone and 
hyperresponsiveness (Figure 1).3,8,37
Limited number of reports deal with the L-arginine–
ADMA homeostasis in context of COPD. Nonetheless, 
the ADMA level in our cross-sectional study (0.58 [IQR: 
0.44–0.66] μmol/L) is comparable with that found by others. 
In a recent study of elderly patients suffering from COPD, 
serum ADMA levels did not show significant alteration when 
compared with age- and gender-matched controls, as ADMA 
levels were 0.319±2.87 μmol/L and 0.318±0.389 μmol/L 
for COPD and control patients, respectively.4 Others 
reported somewhat higher ADMA levels in COPD (and 
ACOS): (0.70±0.35 μmol/L,38 0.766±0.01 μmol/L,3 and 
0.63 [IQR: 0.57–0.72] μmol/L6). Results of the two latter 
patient groups were contrasted with serum ADMA levels 
of age-matched control groups (0.479±0.06 μmol/L3 and 
0.41 [IQR: 0.38–0.46] μmol/L6). It may be argued that these 
systemic levels are in the range considered to be normal 
(0.4–1.0 μmol/L).3,4,6,8 Regardless, ADMA may assume 
central importance in the etiopathogenesis of COPD if one 
Figure 3 The model describing the correlation between (log transformed values of) 
raw and serum concentration of aDMa in the whole data set (n=74).
Notes: The x-axis shows the common logarithm of serum aDMa concentration 
(in μmol/l), while the y-axis denotes the common logarithm of raw (in kPa⋅s/l). The 
blue and red dots indicate the raw (ie, original) values and fitted values obtained 
by multiple linear regression, respectively. The green and orange lines indicate the 
curves fitted to the raw data and to data provided by multiple linear regression. 
Fitting was done by locally weighted scatterplot smoothing (lowess).
Abbreviations: raw, airway resistance; aDMa, asymmetric dimethylarginine.
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considers that serum ADMA levels may be considerably 
lower than the intracellular levels, while ADMA exerts its 
above-mentioned effects intracellularly. This assumption is 
corroborated by the finding that lung ADMA concentration 
is one of the highest in the body, and thus, it is likely that 
even a small increase in the systemic ADMA level reflects 
significant changes in the pulmonary compartment,39 lead-
ing to potentially deleterious effects in the airways and lung 
parenchyma.
Upon comparing these findings to the results obtained by 
analyzing the relationship between R
aw
 and ADMA in a larger 
(n=154) cohort of BA patients (Tajti et al, unpublished data, 
2017) receiving adequate asthma controller therapy, several 
conclusions may be drawn. Although the final multiple linear 
regression model did show significant correlation between 
R
aw
 and ADMA, the correlation coefficient was considerably 
lower in the BA cohort (β: 0.22; CI: 0.054, 0.383; P=0.01) 
than in the COPD cohort (β: 0.42; CI: 0.06, 0.77; P=0.022). 
Moreover, the final model of BA patients did not contain 
CRP, a ubiquitous marker of inflammation. These findings 
apparently corroborate the previous proposition that the 
nature of inflammation differs in these two chronic inflamma-
tory diseases which is reflected by a distinct cytokine profile.40 
For example, enhanced activity of nuclear factor (NF)-κB, a 
corticosteroid-responsive transcriptional factor,41 was shown 
in BA.40 In COPD, however, although reports showed that 
the expression profile of NF-κB is altered, its resistance to 
inhaled corticosteroid therapy was also proposed.42 In the 
case of the BA patients receiving inhaled corticosteroids, 
we could not detect signs of systemic inflammation; that is 
CRP, fibrinogen, and procalcitonin levels were in the normal 
range (Tajti et al, unpublished data, 2017). To explain this 
finding, we presumed that inhibition of NF-κB expression 
with corticosteroid therapy suppressed the induction of iNOS 
and the consequent abundant peroxynitrite formation. Thus, 
the effect of ADMA on processes affecting R
aw
 was limited 
to the inhibition of constitutive NOS isoforms that led to 
NO deficiency and an increased R
aw
. In COPD, however, we 
found evidence of a systemic low-grade inflammation that 
may induce iNOS in a manner independent of NF-κB activa-
tion (increase of interferon-γ is known in COPD, and it may 
induce iNOS by activating a distinct enhancer region)41 that 
leads to enhanced oxidative stress. The resulting peroxynitrite 
can further increase the activity of arginase43,44 that impairs 
the balance of arginase and NOS pathways as reported by 
others (Figure 1).6,14 These synergistic processes present in 
COPD all contribute to the evolution of pulmonary inflam-
mation, oxidative stress, airway remodeling, and consequent 
airflow limitation. This may possibly be reflected by the more 
pronounced relationship between R
aw
 and ADMA.
A possible limitation of the present study is stemming 
from its cross-sectional design that inherently limits the 
possibility to draw cause-and-effect conclusions. Meticulous 
care was taken to overcome this shortcoming by collecting 
information regarding the possible confounders and using 
multiple linear regression to correct for them. Lack of post-
bronchodilator whole-body plethysmography may be further 
considered as a shortcoming. Nevertheless, this patient 
population was enrolled in a COPD management program 
for a median of 5 (IQR: 3–10) years. Accordingly, all patients 
were receiving some form of bronchodilator therapy and were 
instructed to take their medications as usual on the morning 
of the examinations. Therefore, these results should be inter-
preted as on-treatment result. Furthermore, the current study 
does not have the means to offer a comprehensive overview 
of relevant biochemical properties and regulatory processes 
related to the NOS and arginase pathways of L-arginine. 
Starting from this, further prospective studies are needed 
to corroborate the hypothetical notions made based on the 
results of our current study. Nevertheless, this investigation 
has several merits like the relatively large clinical patient 
sample, the use of special tools (whole-body plethysmogra-
phy enabling direct assessment of R
aw
, and SGRQ, a validated 
disease-specific questionnaire), and furthermore, the stringent 
data analysis resulting in powerful findings.
Conclusion
We found a significant positive linear relationship between 
R
aw
 and ADMA in a cohort of COPD patients who had 
evidence of a persistent low-grade systemic inflamma-
tion. The strong correlation between R
aw
 and ADMA was 
even more explicit in the group experiencing worse COPD 
control leading to more severe symptoms. Based on our 
results, we proposed that ADMA influences the evolution 
and progression of COPD. Mechanisms of ADMA’s effect 
on R
aw
 in COPD may consist of an increase in oxidative 
stress mediated by products of uncoupled NOS (especially 
iNOS upregulated by inflammation), by NO deficiency 
resulting from a competitive inhibition of NOS, and by an 
increase of arginase activity leading to fibrosis and airway 
remodeling.
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